X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Nippon Chemiphar announces positive results from phase-1 trial of NC-2500, a novel XOR inhibitor

Yuvraj_pawp by Yuvraj_pawp
30th November 2017
in Clinical Trials

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Nippon Chemiphar has announced that the phase-1 clinical trial of NC-2500, a novel xanthine oxidoreductase (XOR) inhibitor, was completed, indicating that it has potential to reduce the risk of gout flare, one of major issues of current treatments for hyperuricemia/gout. The randomized, single-blind, placebo-controlled, dose-escalation study was conducted to evaluate safety, pharmacological characteristics and pharmacokinetics of NC-2500 in healthy volunteers with single and multiple dosing, once daily for 7 days.

NC-2500 showed favorable urate-lowering properties which may make a difference in gout treatment. NC-2500 lowered serum urate levels gradually to the same extent as current XOR inhibitors through 7 days, which could decrease the risk of acute flare in gout. Acute flare due to rapid urate reduction is one of the major issues in the initial phase of current therapy, which impairs patients’ quality of life and adherence, frequently resulting in failing sufficient control of serum urate and then worsening the disease. NC-2500 is expected to have potential to resolve these issues by its unique urate-lowering property to avoid acute flare, with no or minimal titration. As for safety, NC-2500 was well-tolerated and adverse events were infrequent, transient, mild, and comparable to placebo. Furthermore, NC-2500 was hardly excreted through the kidneys, which can be a favorite profile for patients with renal impairment, frequently observed in gout.

Nippon Chemiphar also completed pre-clinical studies on NC-2700, a novel urate transporter 1 (URAT1) inhibitor, enhancing excretion urate to urine. NC-2700 showed not just a potent uricosuric effect, but also pH-raising of the urine with lowered pH in an animal model, which could decrease the risk of renal calculus and nephrotoxicity with urate crystals in the urine, the most common issue with uricosuric therapy. NC-2700 is now ready for a phase-1 clinical study.

Focusing on research in hyperuricemia/gout, Nippon Chemiphar has been developing NC-2500 and NC-2700, attractive product candidates which may resolve current issues in treating gout and offer new treatment options to patients for their better outcomes and quality of life. To accelerate development and make them available for patients earlier, Nippon Chemiphar is considering collaboration or partnering for further development and welcomes proposals.

Previous Post

Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan

Next Post

Merck, Pfizer announce phase III JAVELIN Gastric 300 trial in patients with pre-treated advanced gastric cancer fails to meet primary endpoint

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
Breast Cancer Therapy
Clinical Trials

US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

27th September 2025
Sensor Technology
Clinical Trials

Enhancing Clinical Research with Advanced Sensor Technology

11th September 2025
Agentic AI in Pharma Transforming RD to Commercialisation
Clinical Trials

Agentic AI in Pharma: Transforming R&D to Commercialisation

31st July 2025
The Future of Clinical
Clinical Trials

The Future of Clinical Trial Data in Decentralisation Models

30th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Next Post

Merck, Pfizer announce phase III JAVELIN Gastric 300 trial in patients with pre-treated advanced gastric cancer fails to meet primary endpoint

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In